These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 33215342)

  • 21. Clinicopathological and Molecular Characteristics of
    Bae H; Lee B; Hwang S; Lee J; Kim HS; Suh YL
    Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.
    Zhang Y; Lucas CG; Young JS; Morshed RA; McCoy L; Oberheim Bush NA; Taylor JW; Daras M; Butowski NA; Villanueva-Meyer JE; Cha S; Wrensch M; Wiencke JK; Lee JC; Pekmezci M; Phillips JJ; Perry A; Bollen AW; Aghi MK; Theodosopoulos P; Chang EF; Hervey-Jumper SL; Berger MS; Clarke JL; Chang SM; Molinaro AM; Solomon DA
    Neuro Oncol; 2022 Oct; 24(10):1749-1762. PubMed ID: 35395677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
    Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
    Reuss DE; Kratz A; Sahm F; Capper D; Schrimpf D; Koelsche C; Hovestadt V; Bewerunge-Hudler M; Jones DT; Schittenhelm J; Mittelbronn M; Rushing E; Simon M; Westphal M; Unterberg A; Platten M; Paulus W; Reifenberger G; Tonn JC; Aldape K; Pfister SM; Korshunov A; Weller M; Herold-Mende C; Wick W; Brandner S; von Deimling A
    Acta Neuropathol; 2015 Sep; 130(3):407-17. PubMed ID: 26087904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
    Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
    J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of imaging for the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update.
    Lundy P; Domino J; Ryken T; Fouke S; McCracken DJ; Ormond DR; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):95-120. PubMed ID: 33215340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Characterization of "True" Low-Grade IDH-Wildtype Astrocytomas.
    Richardson TE; Hatanpaa KJ; Walker JM
    J Neuropathol Exp Neurol; 2021 Apr; 80(5):431-435. PubMed ID: 33829259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases.
    Kibe Y; Ohka F; Aoki K; Yamaguchi J; Motomura K; Ito E; Takeuchi K; Nagata Y; Ito S; Mizutani N; Shiba Y; Maeda S; Nishikawa T; Shimizu H; Saito R
    Acta Neuropathol Commun; 2024 Apr; 12(1):57. PubMed ID: 38605367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
    Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults.
    Redjal N; Nahed BV; Dietrich J; Kalkanis SN; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):165-213. PubMed ID: 33215343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis.
    Appin CL; Brat DJ
    Adv Anat Pathol; 2015 Jan; 22(1):50-8. PubMed ID: 25461780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
    Weller M; Reifenberger G
    Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular GBM versus Histopathological GBM: Radiology-Pathology-Genetic Correlation and the New WHO 2021 Definition of Glioblastoma.
    Agarwal A; Edgar MA; Desai A; Gupta V; Soni N; Bathla G
    AJNR Am J Neuroradiol; 2024 Aug; 45(8):1006-1012. PubMed ID: 38438167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
    Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
    J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
    Lee M; Kang SY; Suh YL
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical, qualitative imaging biomarkers, and tumor oxygenation imaging biomarkers for differentiation of midline-located IDH wild-type glioblastomas and H3 K27-altered diffuse midline gliomas in adults.
    Sim Y; Choi SH; Lee N; Park YW; Ahn SS; Chang JH; Kim SH; Lee SK
    Eur J Radiol; 2024 Apr; 173():111384. PubMed ID: 38422610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients.
    Rosager AM; Dahlrot RH; Sørensen MD; Bangsø JA; Hansen S; Kristensen BW
    J Neuropathol Exp Neurol; 2022 Jan; 81(1):54-60. PubMed ID: 34875075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.